{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-207397","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.034042+00:00","generated_at":"2026-06-11T21:12:09.894395+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inovio Q2 net loss $35.5M; stops VGX-3100 cervical program, cuts 30% staff","bullets":["Net loss of $35.5M ($0.13 per share) on revenue of $226K; cash, equivalents & short-term investments $194.9M.","Ceasing U.S. development of VGX-3100 for cervical HSIL after biomarker analysis; shifting focus to INO-3107 Phase 3 for RRP targeted for Q1 2024.","Reducing workforce by 58 employees (30%) for ~$9.9M annual savings; cash runway extended into Q3 2025.","R&D expenses fell to $23.7M from $56.5M; G&A dropped to $13.5M from $48.5M YoY, partly due to lower COVID-related costs and litigation settlement.","ApolloBio continues VGX-3100 Phase 3 for cervical HSIL in China; INOVIO exploring anal HSIL and other pipeline candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-207397","json":"https://secwatch.observer/filing/0001193125-23-207397.json","markdown":"https://secwatch.observer/filing/0001193125-23-207397.md","text":"https://secwatch.observer/filing/0001193125-23-207397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523207397/0001193125-23-207397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523207397/d538749d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:12:09.894395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7eccec0acbe0614a8e5ed6c4ddda6c1af643ebd","claim":"INOVIO PHARMACEUTICALS, INC. reported financial results for quarter and six months ended June 30, 2023.","evidence_excerpt":"On August 9, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312523207397/0001193125-23-207397-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}